State Street SPDR S&P Biotech ETF
702 hedge funds and large institutions have $7.56B invested in State Street SPDR S&P Biotech ETF in 2021 Q4 according to their latest regulatory filings, with 140 funds opening new positions, 211 increasing their positions, 199 reducing their positions, and 63 closing their positions.
122% more first-time investments, than exits
New positions opened: 140 | Existing positions closed: 63
11% more funds holding
Funds holding: 635 → 702 (+67)
6% more repeat investments, than reductions
Existing positions increased: 211 | Existing positions reduced: 199
0% more funds holding in top 10
Funds holding in top 10: 20 → 20 (0)
5% less capital invested
Capital invested by funds: $7.94B → $7.56B (-$388M)
5.63% less ownership
Funds ownership: 111.08% → 105.45% (-5.6%)
21% less call options, than puts
Call options by funds: $2.63B | Put options by funds: $3.35B
Top Buyers
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$265M |
| 2 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$211M |
| 3 |
Jane Street
New York
|
+$181M |
| 4 |
MCM
Moore Capital Management
New York
|
+$161M |
| 5 |
Goldman Sachs
New York
|
+$148M |
Top Sellers
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$492M |
| 2 |
JP Morgan Chase
New York
|
-$292M |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$238M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$197M |
| 5 |
CAC
Cowen and Company
New York
|
-$50.3M |
XBI Hedge Fund Activity: Q4 2021 in Review
702 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q4 2021, worth a combined $7.56B — down 4.9% from $7.94B a quarter earlier.
Buyers outnumbered sellers: 140 funds opened new XBI positions and 63 closed out — a net gain of 77 holders — while 211 added to existing stakes and 199 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $265M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $492M.
- 702 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q4 2021, up from 635 in Q3 2021.
- Funds reported $7.56B of State Street SPDR S&P Biotech ETF stock for Q4 2021, down 4.9% quarter-over-quarter.
- 140 funds opened new State Street SPDR S&P Biotech ETF positions in Q4 2021 and 63 closed out, a net change of +77 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q4 2021 was Boxer Capital, an estimated $265M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q4 2021 was BNP Paribas Financial Markets, an estimated $492M sold.
Based on aggregated 13F filings for Q4 2021.